164 related articles for article (PubMed ID: 19365011)
1. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.
Wroblewski JJ; Wells JA; Adamis AP; Buggage RR; Cunningham ET; Goldbaum M; Guyer DR; Katz B; Altaweel MM;
Arch Ophthalmol; 2009 Apr; 127(4):374-80. PubMed ID: 19365011
[TBL] [Abstract][Full Text] [Related]
2. Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion.
Wroblewski JJ; Wells JA; Gonzales CR
Am J Ophthalmol; 2010 Jan; 149(1):147-54. PubMed ID: 19875087
[TBL] [Abstract][Full Text] [Related]
3. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
Brown DM; Campochiaro PA; Singh RP; Li Z; Gray S; Saroj N; Rundle AC; Rubio RG; Murahashi WY;
Ophthalmology; 2010 Jun; 117(6):1124-1133.e1. PubMed ID: 20381871
[TBL] [Abstract][Full Text] [Related]
4. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.
Cunningham ET; Adamis AP; Altaweel M; Aiello LP; Bressler NM; D'Amico DJ; Goldbaum M; Guyer DR; Katz B; Patel M; Schwartz SD;
Ophthalmology; 2005 Oct; 112(10):1747-57. PubMed ID: 16154196
[TBL] [Abstract][Full Text] [Related]
5. A phase 2/3, multicenter, randomized, double-masked, 2-year trial of pegaptanib sodium for the treatment of diabetic macular edema.
Sultan MB; Zhou D; Loftus J; Dombi T; Ice KS;
Ophthalmology; 2011 Jun; 118(6):1107-18. PubMed ID: 21529957
[TBL] [Abstract][Full Text] [Related]
6. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study.
Boyer D; Heier J; Brown DM; Clark WL; Vitti R; Berliner AJ; Groetzbach G; Zeitz O; Sandbrink R; Zhu X; Beckmann K; Haller JA
Ophthalmology; 2012 May; 119(5):1024-32. PubMed ID: 22440275
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study.
Kinge B; Stordahl PB; Forsaa V; Fossen K; Haugstad M; Helgesen OH; Seland J; Stene-Johansen I
Am J Ophthalmol; 2010 Sep; 150(3):310-4. PubMed ID: 20591399
[TBL] [Abstract][Full Text] [Related]
8. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.
Heier JS; Clark WL; Boyer DS; Brown DM; Vitti R; Berliner AJ; Kazmi H; Ma Y; Stemper B; Zeitz O; Sandbrink R; Haller JA
Ophthalmology; 2014 Jul; 121(7):1414-1420.e1. PubMed ID: 24679444
[TBL] [Abstract][Full Text] [Related]
9. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study.
Campochiaro PA; Heier JS; Feiner L; Gray S; Saroj N; Rundle AC; Murahashi WY; Rubio RG;
Ophthalmology; 2010 Jun; 117(6):1102-1112.e1. PubMed ID: 20398941
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab for macular edema in central retinal vein occlusion: a prospective, randomized, double-masked clinical study.
Epstein DL; Algvere PV; von Wendt G; Seregard S; Kvanta A
Ophthalmology; 2012 Jun; 119(6):1184-9. PubMed ID: 22424833
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS study.
Brown DM; Heier JS; Clark WL; Boyer DS; Vitti R; Berliner AJ; Zeitz O; Sandbrink R; Zhu X; Haller JA
Am J Ophthalmol; 2013 Mar; 155(3):429-437.e7. PubMed ID: 23218699
[TBL] [Abstract][Full Text] [Related]
12. Reading speed improvements in retinal vein occlusion after ranibizumab treatment.
Suñer IJ; Bressler NM; Varma R; Lee P; Dolan CM; Ward J; Colman S; Rubio RG
JAMA Ophthalmol; 2013 Jul; 131(7):851-6. PubMed ID: 23699977
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.
Korobelnik JF; Holz FG; Roider J; Ogura Y; Simader C; Schmidt-Erfurth U; Lorenz K; Honda M; Vitti R; Berliner AJ; Hiemeyer F; Stemper B; Zeitz O; Sandbrink R;
Ophthalmology; 2014 Jan; 121(1):202-208. PubMed ID: 24084497
[TBL] [Abstract][Full Text] [Related]
14. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.
Campochiaro PA; Brown DM; Awh CC; Lee SY; Gray S; Saroj N; Murahashi WY; Rubio RG
Ophthalmology; 2011 Oct; 118(10):2041-9. PubMed ID: 21715011
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two doses of intravitreal bevacizumab as primary treatment for macular edema secondary to central retinal vein occlusion: results of the pan American collaborative retina study group at 24 months.
Wu L; Arevalo JF; Berrocal MH; Maia M; Roca JA; Morales-Cantón V; Alezzandrini AA; Díaz-Llopis MJ
Retina; 2010; 30(7):1002-11. PubMed ID: 20616679
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.
Ogura Y; Roider J; Korobelnik JF; Holz FG; Simader C; Schmidt-Erfurth U; Vitti R; Berliner AJ; Hiemeyer F; Stemper B; Zeitz O; Sandbrink R;
Am J Ophthalmol; 2014 Nov; 158(5):1032-8. PubMed ID: 25068637
[TBL] [Abstract][Full Text] [Related]
17. Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study.
Epstein DL; Algvere PV; von Wendt G; Seregard S; Kvanta A
Ophthalmology; 2012 Dec; 119(12):2587-91. PubMed ID: 22902212
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal ranibizumab (Lucentis) for branch retinal vein occlusion-induced macular edema: nine-month results of a prospective study.
Rouvas A; Petrou P; Ntouraki A; Douvali M; Ladas I; Vergados I
Retina; 2010 Jun; 30(6):893-902. PubMed ID: 20531142
[TBL] [Abstract][Full Text] [Related]
19. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials.
; D'Amico DJ; Masonson HN; Patel M; Adamis AP; Cunningham ET; Guyer DR; Katz B
Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134
[TBL] [Abstract][Full Text] [Related]
20. Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion.
Rensch F; Jonas JB; Spandau UH
Acta Ophthalmol; 2009 Feb; 87(1):77-81. PubMed ID: 18937800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
